Physician profile
Amanda Boyd
NPI 1609262450
$2,618.82
in general payments reported to CMS, 2019-2025
24 companies · $1,226 in 2025
The $1,226 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $112 · 2023: $347 · 2024: $934 · 2025: $1,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,477 · Education: $29.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,477.09 |
| Education | $29.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $539.75 | 2022-2025 | Rinvoq, Mavyret |
| Takeda Pharmaceuticals U.S.A., INC. | $432.08 | 2022-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.07 | 2022-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $168.16 | 2023-2025 | Stelara, Tremfya |
| Gilead Sciences, INC. | $164.78 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $141.76 | 2022-2025 | Dupixent |
| Alnylam Pharmaceuticals INC. | $126.32 | 2023-2024 | Givlaari |
| Ardelyx, INC. | $111.92 | 2023-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $103.22 | 2024-2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $102.24 | 2023-2025 | Linzess |
| Medtronic, INC. | $68.09 | 2025 | Gi Genius |
| Qol Medical, LLC | $67.01 | 2024-2025 | Sucraid, Sucraid |
| Fujifilm Healthcare Americas Corporation | $56.94 | 2025 | |
| Celltrion USA INC. | $49.09 | 2024-2025 | Zymfentra, Vegzelma |
| Boston Scientific Corporation | $48.84 | 2024 | Orcapod |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $44.51 | 2024-2025 | Injectafer |
| Ferring Pharmaceuticals INC. | $40.55 | 2025 | Rebyota |
| Owlet Baby Care, INC. | $40.42 | 2025 | Babysat 3 Rx Sensor, Babysat 3 Rx App, Babysat 3 Rx Base Station |
| Celgene Corporation | $39.72 | 2023-2024 | Zeposia |
| Ultragenyx Pharmaceutical INC. | $27.34 | 2022 | |
| Lilly USA, LLC | $20.58 | 2025 | Omvoh |
| Novo Nordisk INC | $19.92 | 2025 | Wegovy |
| Sandoz INC. | $18.32 | 2025 | Hyrimoz |
| Evoke Pharma, INC. | $16.19 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.